Taro Pharmaceutical Industries Ltd. (TARO)

42,19 -0,11 (-0,26%) Börsenschluss: 04:00PM EDT

Taro Pharmaceutical Industries Ltd.

14 Hakitor Street
Haifa Bay
Haifa 2624761
Israel
972 4 847 5700
https://www.taro.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 1.554

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Uday V. Baldota	CEO & Director	N/A	N/A	1970
Mr. William J. Coote	VP, CFO & Chief Accounting Officer	N/A	N/A	1955
Mr. Itamar Karsenti	VP & Head of Operations	N/A	N/A	1972
Mr. Avi Avramoff	VP and Head of R&D	N/A	N/A	1965
Mr. Itzik Baruch	Vice President of Technical Services	N/A	N/A	1963
Dr. Roman Kaplan	Vice President of Scientific and Technical Compliance Manager	N/A	N/A	1947
Mr. Erik Zwicker J.D.	VP, General Counsel & Secretary	N/A	N/A	1980
Mr. Ara Aprahamian	Vice President of Sales & Marketing	616,14k	N/A	1968
Ms. Michele Visosky	VP & Head of Human Resource	N/A	N/A	1966
Mr. Jayesh Shah	Head of Procurement	N/A	N/A	1956

Die Beträge haben den Stand 31. Dezember 2017 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Corporate Governance

Taro Pharmaceutical Industries Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.